Objective. Aggrecan enables articular cartilage to bear load and resist compression. Aggrecan loss occurs early in osteoarthritis and rheumatoid arthritis and can be induced by inflammatory cytokines such as interleukin-1 (IL-1). IL-1 induces cleavage of specific aggrecans characteristic of the ADAMTS proteinases. The aim of this study was to identify the intracellular signaling pathways by which IL-1 causes aggrecan degradation by human chondrocytes and to investigate how aggrecanase activity is controlled by chondrocytes.
domain of aggrecan interacts with hyaluronic acid to form giant aggregates, which are trapped in the collagen fiber mesh (3) .
The turnover of aggrecan is controlled extracellularly by proteinases, the most important of which cleave it N-terminally to alanines 374 and 1820, releasing large C-terminal fragments from the aggregates (4) . These aggrecanases belong to the ADAMTS family (5, 6) . Cartilage from ADAMTS-5 2/2 mice did not show accelerated aggrecan degradation in response to IL-1, and deletion of ADAMTS-5 prevented cartilage damage in murine models of autoimmune inflammatory arthritis and OA (7, 8) . ADAMTS-4, the first aggrecanase identified, may also be involved in cartilage degradation. Although ADAMTS-4 has not been observed to play a role in murine cartilage, it has been implicated in human cartilage aggrecan degradation in experiments using RNA interference (RNAi) (9) . The activity of these enzymes is prevented by tissue inhibitor of metalloproteinases 3 (TIMP-3), which is produced by chondrocytes and many other cell types (10, 11) . Thus, the evidence from experiments in ADAMTS-5 2/2 mice strongly suggests that IL-1 works by increasing the activity of ADAMTS-5. However, the mechanism of this is unknown: expression of the enzyme might be increased, or TIMP-3 levels may be reduced, by IL-1 stimulation.
The intracellular signaling mechanisms by which IL-1 causes chondrocytes to degrade aggrecan are also unknown. IL-1 receptor type I (IL-1RI) signals via IL-1R-associated kinase 1 (IRAK-1) and IRAK-4 to activate tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF-6), an E3 ubiquitin ligase. TRAF-6 forms K 63 -linked polyubiquitin chains that bind transforming growth factor b-activated kinase 1 (TAK-1) via TAK-1-associated binding protein, causing activation of TAK-1 (12) . This in turn activates a core of 4 major pathways involving protein kinases: the canonical pathway that activates the transcription factor NF-kB and the 3 MAPK cascades (ERK, JNK, and p38). Genes whose transcriptional expression increases in the setting of inflammation are typically regulated by NF-kB. Their promoters also commonly contain binding sites for activator protein 1 (AP-1) transcription factors such as c-Jun, which is activated by JNK (13) , and for CCAAT/ enhancer binding protein b (also known as NF-IL6), which is activated by ERK (14) . MAPK p38 controls the stability of many transcripts of the inflammatory response but can also phosphorylate transcription factors (15) .
The aim of this study was to gain insight into the molecular mechanisms by which IL-1 stimulates human articular chondrocytes to degrade aggrecan. We observed that aggrecan degradation was mainly dependent on ADAMTS-5, and that this response was strikingly mediated by JNK-2. IL-1 did not cause increased production of ADAMTS-5; rather, it apparently reduced its endocytic uptake via low-density lipoprotein receptor-related protein 1 (LRP-1) by causing increased shedding of LRP-1.
MATERIALS AND METHODS
Reagents and antibodies. Anti-TRAF-6 (80285), anti-TAK-1 (D94D7), anti-MKK-4 (9152S), anti-p-MKK- 4 ) (44682G) was obtained from Invitrogen, anti-ERK (sc-94) was obtained from Santa Cruz Biotechnology, anti-AGEG was raised as described previously (16) , and anti-LRP-1 (8G1) and anti-ARGS (ab3773) were obtained from Abcam. TAK-1 inhibitor (5Z)-7-oxozeanol was obtained from Tocris, neddylation inhibitor MLN4924 was obtained from Active Bioscience, and MEK inhibitor U0126 and p38 inhibitor SB201920 were obtained from Promega. Recombinant human C-terminal His-tagged human receptor-associated protein (RAP) was produced in Escherichia coli using a pET3a-based expression vector and purified as described previously (17) . Bovine aggrecan was purified from bovine nasal cartilage (18) . A TIMP-3 enzyme-linked immunosorbent assay (ELISA) (DuoSet) was obtained from R&D Systems (DY973), and an Aggrecanase Activity Assay (M046008) was obtained from MD Biosciences.
Cartilage tissue preparation and isolation of human chondrocytes. Samples of normal cartilage were obtained, with informed consent according to local ethics committee guidelines, from the femoral condyle and tibial plateau in 26 patients undergoing surgery for tumors not involving the joint (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.39099/abstract). Full-thickness (;1.5-mm 3 ) explants (3 pieces per time point; 120 mg cartilage/ml medium) were cultured in 48-well plates containing serum-free Dulbecco's modified Eagle's medium (DMEM) (4.5 gm/liter glucose with L-glutamine), 1% penicillin/streptomycin, and amphotericin for 24 hours. The medium was replaced with serum-free medium containing the inhibitor being tested, with or without IL-1 (50 ng/ml), and then incubated for a further 24 hours. Conditioned medium was harvested and treated as described below for detection of aggrecan cleavage.
To prepare human articular chondrocytes, freshly harvested human cartilage was chopped finely and placed in DMEM containing 10% fetal calf serum (Invitrogen) and 1.5 mg/ml type II collagenase (Roche). It was then incubated at 37 C for 18-24 hours with shaking at 180 revolutions per minute. Chondrocytes were passed through a cell strainer, pelleted, and washed twice with medium. Cells were seeded at a density of 2 million cells in 10-cm 2 tissue culture plates or 6 million cells in 15-cm 2 tissue culture plates in complete DMEM containing 10% fetal bovine serum, 1% penicillin/ streptomycin, and amphotericin. Chondrocyte cultures (passage 0) were left undisturbed for 7 days and then passaged at confluence. To ensure efficient transfection, passaged human chondrocytes (passages 2-3) were used for small interfering RNA (siRNA) experiments. Passaged chondrocytes may have undergone a degree of dedifferentiation. The morphology of the cells was not changed by IL-1 or siRNA treatment.
Small interfering RNA transfection. Human articular chondrocytes were transfected as described previously (19) . Briefly, chondrocytes were plated at 300,000 cells/well in 6-well plates. The following day, transfection with the siRNA of interest was carried out at a final concentration of 10-30 nM, using Lipofectamine 2000 (Invitrogen) for 4 hours in serum-free Opti-MEM I. Cells were then incubated in complete medium for 72 hours to allow efficient knockdown. Following incubation, the medium was changed to a serum-free medium containing the appropriate stimulus and/or inhibitor, according to the experiment design. Gene-specific siRNAs were obtained from Ambion. The siRNA oligos are as follows: ADAMTS-4 (s18227), ADAMTS-5 (s368), TRAF-6 (s14389), TAK-1 (s13767), MKK-4 (s12703), JNK-1 (s11152), JNK-2 (s229708, s229709), JNK-3 (s11161), and TIMP-3 (s14146).
Detection of aggrecan degradation in chondrocyte culture medium using an aggrecan overlay assay. Chondrocytes were overlaid with sterile filtered bovine aggrecan (25-50 mg/ml) in serum-free DMEM in the presence or absence of IL-1 (50 ng/ml), according to the experimental set-up. Medium harvested from the cultures was processed to detect the aggrecanasegenerated fragments, as described previously (20) . Briefly, proteoglycans were extracted from the medium samples and deglycosylated in sodium acetate buffer with keratanase II (0.001 units/mg glycosaminoglycan [GAG] ; Sigma) and chondroitinase ABC (0.001 units/mg GAG; Sigma). Proteins were then precipitated using ice-cold acetone and analyzed by Western blotting. Monoclonal antibody BC-3, which recognizes N-terminal ARGS, was used to detect fragments generated by cleavage of aggrecan at the Asn 373 -Ala 374 bond (21) , and a polyclonal rabbit antibody directed at N-terminal AGEG was used to detect fragments generated by cleavage at the Glu 1819 -Ala 1820 bond (16) . ELISA for aggrecanase activity. An Aggrecanase Activity Assay (MD Biosciences) was used to measure activity in cell culture medium, according to the manufacturer's instructions. This assay consists of 2 modules, the Aggrecanase Module and the ELISA Module. A recombinant fragment of human aggrecan interglobular domain is first digested with the sample of culture medium being tested. Aggrecanase cleavage of the substrate releases a peptide with the N-terminal sequence ARGSVIL (ARGSVIL peptide). The ARGSVIL peptide is then quantified with 2 antipeptide monoclonal antibodies.
Adenoviral infection of chondrocytes and NF-kB luciferase reporter assay. Chondrocytes in a 6-12-well plate were infected with adeno-IkBa nonphosphorylatable mutant, adeno-empty vector, and/or adeno-NF-kB luciferase reporter virus (AdNF-kB-Luc), as described previously (22) . Culture medium was harvested for analysis of aggrecan fragments AGEG and ARGS by Western blotting as described above for the aggrecan overlay assay, while the cell layer was used for NF-kB luciferase reporter assay.
RNA extraction and real-time quantitative reverse transcription-polymerase chain reaction (PCR). Total RNA was extracted from cells using a Qiagen RNeasy Mini Kit according to the manufacturer's instructions. Complementary DNA Arrows indicate aggrecanase-specific cleavages that generate ARGS and AGEG fragments. B, Left, Human cartilage explants were adapted to culture for 24 hours at 37 C and then were left untreated or were treated with IL-1 (50 ng/ml). Medium was then processed and blotted for the ARGS and AGEG neoepitopes. Right, Human articular chondrocytes were cultured in 6-well plates (3 3 10 5 cells/well) at 37 C for 24 hours. Cells were then overlaid with bovine aggrecan (50 mg/ml) with or without IL-1 (50 ng/ml) for 24 hours. The medium was processed, and Western blotting was performed. C, Chondrocytes were cultured as described in B. Cells were transfected with 20 nM small interfering RNA (siRNA) against ADAMTS-4 and ADAMTS-5 or with scrambled siRNA (control [CTRL]) as described in Materials and Methods. After 72 hours, cells were overlaid with bovine aggrecan (50 mg/ml) with or without IL-1 (50 ng/ml) for 24 hours. The medium was processed, and Western blotting was performed. D, Top, Inhibition of AGEG generation by the knockdowns was determined by densitometric analysis of the IL-1 panels of the AGEG blots shown in C. Values are the mean 6 SEM. ** 5 P , 0.01; *** 5 P , 0.001 versus control, by unpaired t-test. Bottom, The knockdown efficiencies for ADAMTS-4 and ADAMTS-5 were measured by quantitative reverse transcription-polymerase chain reaction. RNAi 5 RNA interference.
(cDNA) was synthesized from total RNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). TaqMan probes for the following genes were obtained from Applied Biosystems: ADAMTS4 (Hs00192708), ADAMTS5 (Hs00199841), JNK1 (Hs00177102), JNK2 (Hs001177012), JNK3 (Hs00373461), NFKBIA (Hs00355671), TIMP3 (Hs00 65949), and GAPDH (Hs0275899). Real-time PCR was performed with a Rotor-Gene 6000 system (Corbett Life Science), using 23 TaqMan MasterMix (Applied Biosystems) according to the manufacturer's instructions. Expression of the respective genes was normalized to that of GAPDH as an internal control, using the DDC t method.
Protein extracts and Western blotting. Chondrocytes were lysed in radioimmunoprecipitation assay buffer containing protease inhibitors. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the transferred membranes were incubated with antibodies against the proteins of interest. For LRP-1 shedding, media were collected and concentrated 10-fold using spin filters. The LRP-1 in medium was analyzed by Western blotting using anti-LRP-1 heavy-chain antibody (8G1).
Statistical analysis. Data for replicate experiments are expressed as the mean 6 SEM. Analysis was performed using Prism 6 software (GraphPad). The level of statistical significance was established using Student's unpaired 2-tailed t-test. P values less than 0.05 were considered significant.
RESULTS
Aggrecan degradation by human chondrocytes is strongly dependent on ADAMTS-5. Ideally, the molecular mechanisms controlling aggrecan turnover could be studied in tissue explants. However, we needed to use RNAi and viral infection as well as pharmacologic reagents and found it difficult to achieve robust reproducible transfection of chondrocytes in intact tissue. We therefore set up a system in which isolated human chondrocytes in monolayer culture caused aggrecan degradation Figure 2 . Essential role for transforming growth factor b-activated kinase 1 (TAK-1) and tumor necrosis factor receptor-associated factor 6 (TRAF-6), the key upstream components of IL-1 signaling pathways, in IL-1-induced degradation of aggrecan. A and B, Chondrocytes (passages 2-4) were cultured as described in Materials and Methods. Cells were transfected with 20 nM siRNA against TRAF-6 (A) or TAK-1 (B), or with scrambled (Sc) siRNA (control). Top, After 72 hours, one set of cells was overlaid with aggrecan (50 mg/ml) with or without IL-1 (50 ng/ ml) in serum-free Dulbecco's modified Eagle's medium for 24 hours, and medium was blotted for the AGEG aggrecan fragment. Middle, Densitometric analysis of the IL-1 panels (n 5 3) for each siRNA was performed. Values are the mean 6 SEM. ** 5 P , 0.01; *** 5 P , 0.001 versus control, by unpaired t-test. Bottom, The second set of cells was treated in the absence or presence of IL-1 (50 ng/ml) for the indicated periods of time, and the cell lysates were analyzed for knockdown efficiency by Western blotting for TRAF-6 (A) or TAK-1 (B), and for phosphorylated TAK-1 (ph-TAK1), as indicated. Total ERK was used as a loading control. C, Human cartilage explants were adapted to culture for 24 hours, then pretreated with or without TAK-1 inhibitor (5Z)-7-Oxozeanol (OXO) for 1 hour. Cartilage explants were then left untreated or were treated with IL-1 (50 ng/ml) for 24 hours. Medium was then blotted for AGEG or ARGS neoepitopes. The graph shows quantification of the AGEG and ARGS blots. See Figure 1 for other definitions.
mirroring that seen in organ culture. Figure 1A shows a simplified diagram of aggrecan interacting with hyaluronan, with the enlarged areas showing the location of the major aggrecanase cleavages immediately before Ala 374 and Ala 1820 (23, 24) . Upon IL-1 stimulation, aggrecan breakdown increased, and the fragments escaped. They were detected, after deglycosylation, by Western blotting with antibodies to the ARGS and AGEG N-terminal neoepitopes. ARGS fragments of M r ;250, ;180, and 70 kd ( Figure 1B ) and an AGEG fragment of M r ;130 kd ( Figure 1B) were observed. Passaged human chondrocytes did not secrete enough aggrecan for cleavage neoepitopes to be detected after IL-1 stimulation. We therefore overlaid the cells with purified full-length bovine aggrecan. When stimulated with IL-1, they generated the 250-kd ARGS and 130-kd AGEG fragments ( Figure 1B ) but not those of 180 kd and 70 kd. The 2 latter fragments may arise because some aggrecan in human articular cartilage is truncated at the C-terminus (24, 25) . The assay system is robust and reproducible, although it does not analyze degradation in a true cell-associated matrix.
We next used siRNA to knock down either ADAMTS-4 or ADAMTS-5 in the chondrocytes before overlaying them with aggrecan substrate and stimulating them with IL-1. Chondrocytes transfected with scrambled-sequence oligonucleotides were always used as controls in the RNAi experiments. Figure 1C shows that both spontaneous generation and IL-1-induced generation of the 250-kd ARGS and 130-kd AGEG fragments were strongly reduced by knocking down ADAMTS-5. Combining results of 3 experiments showed that inhibition of AGEG generation by the knockdowns was 90% for ADAMTS-5 and 25% for ADAMTS-4 ( Figure 1D ). Knockdown efficiencies were .80% ( Figure 1D ). We decided to use the 250-kd ARGS and 130-kd AGEG fragments as indicators of aggrecan degradation stimulated by IL-1.
Necessity of upstream components of IL-1 signaling pathways, TRAF-6 and TAK-1, for IL-1-induced degradation of aggrecan. We next investigated the intracellular signaling pathways controlling aggrecan degradation. IL-1RI activated TAK-1 via TRAF-6. Knocking down either TRAF-6 (Figure 2A) or TAK-1 Figure 3 . NF-kB, p38, or ERK pathways are not essential for interleukin-1 (IL-1)-induced aggrecan degradation in human chondrocytes and human articular cartilage. A-C, Chondrocytes were cultured and then infected with empty adenovirus or adenovirus expressing a nonphosphorylatable mutant of IkBa (mIkBa), as described in Materials and Methods. A, After 24 hours, cells were overlaid with aggrecan (50 mg/ml) in the absence or presence of IL-1 (50 ng/ml) for 24 hours. Medium was then blotted for the ARGS and AGEG neoepitopes. The cells were lysed in radioimmunoprecipitation assay buffer and Western blotted for cyclooxygenase 2 (COX-2) or ERK. B, After cells were infected as described in A, they were stimulated with IL-1 for the indicated periods of time, and then lysates were Western blotted for phosphorylated IkBa (ph-IkBa), IkBa, phosphorylated JNK, and ERK to check for equal protein loading. C, Cells were infected as described in A for 2 hours and then with an NF-kB reporter for another 2 hours. Luciferase activity was measured with a luminometer as described in Materials and Methods. D, Human cartilage explants were adapted to culture for 24 hours and then pretreated with or without inhibitors (NF-kB inhibitor MLN9424, p38 inhibitor SB201920, and ERK inhibitor U0126) for 1 hour at the indicated concentrations. Cartilage explants were then either left untreated or were treated with IL-1 (50 ng/ml) for 24 hours. After incubation, culture medium was blotted for aggrecan fragments containing AGEG and ARGS neoepitopes.
( Figure 2B ) inhibited generation of the AGEG fragment by IL-1. We tested a pharmacologic inhibitor of TAK-1 on cartilage explants in order to validate the results of the chondrocyte experiments. Figure 2C shows that the inhibitor (5Z)-7-oxozeanol (26) blocked IL-1-induced generation of ARGS and AGEG aggrecan fragments in cultured cartilage.
NF-kB, p38, or ERK pathways are not necessary for IL-1-induced aggrecan degradation in human chondrocytes. TAK-1 is involved in the activation of NF-kB that drives transcription of many IL-1-induced genes. We inhibited the canonical pathway of activation by transfecting chondrocytes with adenovirus expressing a nonphosphorylatable mutant form of IkBa (22) . The ability of chondrocytes to generate the ARGS and AGEG fragments in response to IL-1 was unaffected by inhibiting NF-kB, although the induction of cyclooxygenase 2 protein was prevented ( Figure 3A) . To verify that NF-kB was being inhibited by the mutant IkBa, we cotransfected the chondrocytes with an NF-kB reporter ( Figure 3C ). Figure 3B shows the effect of the adenoviral mutant on the total amount of IkB protein in the chondrocytes. The virally expressed protein inhibited the IL-1-induced phosphorylation of endogenous IkB, its degradation after stimulation, and activation of an NF-kB reporter. The mutant IkB had no effect on activation of JNK, as judged by the appearance of the phosphorylated forms upon IL-1 stimulation. To verify that IL-1-induced aggrecan degradation in cartilage tissue was independent of NF-kB, we used the neddylation inhibitor MLN9424, which blocks IkB degradation (27) (Figure 3D ).
TAK-1 also activates the p38 MAPK pathway. There are well-characterized inhibitors for p38, so we tested one of them, SB201920, on cartilage tissue. Figure 3D shows that SB201920 did not affect IL-1-induced aggrecan degradation. In addition, we tested an inhibitor of ERK activation, U0126, because ERK is also activated by IL-1. This actually enhanced the generation of both fragments by cartilage treated with IL-1 ( Figure 3D) .
Dependence of IL-1-induced aggrecan degradation on MKK-4/JNK-2. Having established that NFkB, p38, and ERK were not mediating the IL-1 signal to degrade aggrecan, we examined the JNK pathway. Knockdown of MKK-4, which is a substrate of TAK-1 Figure 4 . MKK-4/JNK-2 pathway regulates IL-1-induced aggrecan degradation in human chondrocytes. A and B, Chondrocytes (passages 2-3) were cultured as described in Materials and Methods. Cells were then transfected with 20-50 nM siRNA against MKK-4 (A), JNK-1, JNK-2, or JNK-3 (B), or with scrambled siRNA (control), as indicated. Cells were left for 72 hours to allow knockdown and then overlaid with aggrecan (50 mg/ml) with or without IL-1 (50 ng/ml) for 24 hours. Medium was blotted for the aggrecan AGEG fragment. Lower blots in A show knockdown efficiency of MKK-4. C, Cells were transfected with 2 oligonucleotides (oligo 1 and oligo 2) directed at JNK-2, and medium was blotted for both ARGS and AGEG aggrecan fragments. Bar graph shows the results of densitometric analysis of IL-1 panels from at least 3 independent experiments. ** 5 P , 0.01; *** 5 P , 0.001; **** 5 P , 0.0001 versus control, by unpaired t-test. D, Cells were cultured and transfected as described in Materials and Methods. After 72 hours, cells were either left untreated or were treated with IL-1 (50 ng/ml) for 5 minutes. Cell lysates were blotted for phosphorylated JNK (ph-JNK), JNK-2, and ERK, as indicated. Bar graph shows expression levels of JNK normalized to GAPDH, as measured by reverse transcription-polymerase chain reaction analysis in extracts of the cells described in C. Values in A, C, and D are the mean 6 SEM (n 5 $3 independent experiments). See Figure 1 for other definitions.
and an activator of JNK, prevented generation of the AGEG aggrecan fragment by IL-1 ( Figure 4A ). In addition, we knocked down MKK-7, which may also be involved in the activation of JNK, but this caused only ;30% reduction in production of AGEG neoepitope (results not shown).
There are 3 JNK genes. Knocking down JNK-2 prevented generation of the AGEG fragment by chondrocytes stimulated with IL-1, while knocking down JNK-1 or JNK-3 had no discernible effect ( Figure 4B ). In a further experiment, 2 different oligonucleotides were used to knock down JNK-2. The generation of both ARGS and AGEG aggrecan fragments by IL-1 stimulation of cells treated with scrambled oligonucleotides was suppressed in those subjected to JNK-2 knockdown ( Figure 4C) . Quantification of the combined experiments showed 80-90% suppression of the aggrecan cleavages induced by IL-1 in the cells in which JNK-2 was knocked down ( Figure 4C ). Knockdown of JNK-2 and JNK-3 messenger RNA (mRNA) was 90% efficient, but that of JNK-1 was only 50% efficient ( Figure 4D ). IL-1 stimulation increased phosphorylation of the 54-kd and 46-kd JNK bands ( Figure 4D ). The 54-kd band was strongly reduced in the JNK-2 knockdown ( Figure  4D ). Western blotting of the 54-kd JNK protein confirmed that the knockdown was efficient ( Figure 4D ).
IL-1 increases aggrecanase activity and enhances LRP-1 shedding via JNK-2. Having established the importance of the JNK pathway for IL-1-induced aggrecan degradation, we investigated the mechanism. The initial experiments (Figure 1) showed that the degradation was mainly attributable to ADAMTS-5 and to a lesser extent to ADAMTS-4. There are no specific sensitive ELISAs or Western blotting antibodies available for these enzymes, but their combined activity can be measured in the culture medium with an assay that uses a recombinant peptide substrate containing the ARGS cleavage site. The cleaved ARGS fragment is detected by ELISA. Aggrecanase activity was barely detectable in medium from resting cultures but was present in that from IL-1-stimulated chondrocytes.
Aggrecanase activity was reduced 70% by knockdown of ADAMTS5 and 20% by knockdown of ADAMTS4 ( Figure 5A ). When JNK2 was knocked down, the activity was reduced by 80% ( Figure 5B ). Knockdown of JNK2 had no effect on basal levels of mRNA for either ADAMTS4 or ADAMTS5 (see Supplementary Figures 1A and B , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.39099/abstract). IL-1 did not alter the expression of ADAMTS5 mRNA but increased that of ADAMTS4 mRNA (see Supplementary Figures 1A  and B) . The IL-1-induced aggrecanase activity was mainly attributable to ADAMTS5, and the expression of ADAMTS-5 mRNA was not significantly increased. It is possible that IL-1 increased the amount of ADAMTS-5 protein without regulating its mRNA. The absolute abundance of ADAMTS-5 transcripts was markedly greater than that of ADAMTS-4 transcripts, even after IL-1 stimulation (see Supplementary Table 2, Figure 5 . Interleukin-1 reduces endocytosis of aggrecanase via JNK-2. Human articular chondrocytes were cultured as described in Materials and Methods and transfected with 20 nM siRNA against ADAMTS-4, ADAMTS-5, JNK-2, and tissue inhibitor of metalloproteinases 3 (TIMP-3), as indicated. Cells were incubated for 72 hours to allow efficient knockdown, overlaid with bovine aggrecan, and then were either left untreated or were treated with IL-1 (50 ng/ml) for 24 hours. A and B, Aggrecanase activity in the culture medium was measured using an Aggrecanase Activity Assay. Activity in the medium from cells treated with scrambled siRNA and IL-1 was set at 100%. ** 5 P , 0.01; **** 5 P , 0.0001 versus control, by unpaired t-test. C and D, Cells were treated with TIMP-3 siRNA or with scrambled siRNA (control) and then were either left untreated or were treated with receptor-associated protein (RAP) (500 nM), in the presence or absence of IL-1 (50 ng/ml). After 24 hours, the aggrecanase activity in the culture medium was measured (C), and the level of TIMP-3 in the culture medium was measured by enzyme-linked immunosorbent assay (D). Values are the mean 6 SEM (n 5 3-4 independent experiments). See Figure 1 for other definitions.
available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39099/abstract). Given that ADAMTS-5 is a 25-fold stronger aggrecanase than ADAMTS-4 (28), this result of knockdown is not surprising.
Another possibility was that IL-1 reduced TIMP-3 levels, thus unmasking enzyme activity. Both ADAMTS enzymes and TIMP-3 are endocytosed by LRP-1 (17, 29, 30) . The steady-state levels of TIMP-3 and aggrecanases reflect the rates of both secretion and uptake by the cells. We reasoned that if we blocked their uptake by LRP-1 with the LRP-like receptor antagonist, RAP (31), and also knocked down TIMP3 (to prevent any inhibition of aggrecanase), we should be able to measure the activity of the total amount of aggrecanase secreted by the cells, assuming there was no other major route of uptake. Adding RAP to the resting chondrocytes increased the aggrecanase activity in the medium 10-50-fold ( Figure 5C ), indicating that in resting cells, 98% of secreted enzyme detected by the Aggrecanase Activity Assay was endocytosed. Knocking down TIMP3 in addition to adding RAP did not significantly increase the amount of aggrecanase activity seen with RAP alone ( Figure 5C ). The efficiency of the knockdown can be seen as the reduction in TIMP-3 protein levels shown in Figure  5D . This result was surprising, because we expected that removing TIMP3 from the system would increase the amount of aggrecanase activity detected, and suggested that in molar terms, much less TIMP3 was being made than active aggrecanase, or conceivably, that other proteinases with higher affinity were making TIMP3 unavailable. Nevertheless, it could be concluded that most of the active aggrecanase detected by the Aggrecanase Activity Assay (and probably the aggrecanase protein secreted) was endocytosed via LRP-1.
We next investigated the effect of IL-1 and observed that stimulation with IL-1 increased the detectable aggrecanase activity ( Figure 5C ). When RAP was added along with IL-1, the activity increased ( Figure 5C ) but was not significantly greater than that observed in the medium of resting cells in the presence of RAP alone ( Figure 5C ). Combining TIMP3 knockdown with the addition of RAP did not further increase the activity produced in the presence of IL-1 ( Figure 5C ). TIMP-3 protein levels in the medium were not significantly changed by IL-1 stimulation ( Figure  5D ), and adding RAP increased the level 3-4-fold (Figure 5D ). We concluded that virtually all of the detectable aggrecanase (mainly ADAMTS-5) that was produced by the chondrocytes is normally endocytosed by LRP-1, thereby keeping extracellular levels low, and that IL-1 did not significantly increase the amount of active aggrecanase synthesized and secreted in the presence of RAP. We reasoned that IL-1 was possibly reducing the amount of aggrecanase endocytosed, and that this was causing increased activity in the medium.
LRP-1 is shed from macrophages stimulated with bacterial lipopolysaccharide (32) and from fibroblasts stimulated with TNF (33) . LRP-1 shedding might reduce surface expression of LRP-1 and thus reduce endocytosis of its ligands. We therefore examined the effect of IL-1 on the expression and shedding of LRP-1. Stimulation with IL-1 increased the amount of LRP-1 shed by chondrocytes and reduced cellular LRP-1 by ;50% during 24-hour culture ( Figures 6A and B) . Cell-surface LRP-1, as measured by fluorescenceactivated cell sorting analysis, showed a similar reduction in the response to IL-1 (results not shown). LRP-1 mRNA was not significantly altered by IL-1 stimulation (see Supplementary Figure 1C , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.39099/abstract). The shedding of LRP-1 induced by IL-1 was prevented by knockdown of JNK2 (Figures 6C and D) . Knockdown did not affect LRP-1 mRNA levels (see Supplementary Figure  1C ). Thus, JNK2-mediated shedding of LRP-1 could cause a reduction in the endocytosis of aggrecanase and increase its concentration in the culture medium during IL-1 stimulation.
DISCUSSION
Aggrecan degradation is traditionally studied in explant cultures, because this keeps the cells in their physiologic extracellular matrix. However, chondrocytes embedded in tissue are very difficult to manipulate by transfection or viral infection. To dissect the molecular mechanisms by which IL-1 causes degradation of aggrecan, we devised a model system in which monolayer cultures of chondrocytes were transfected with oligonucleotide or the virus of interest and then overlaid with a pure aggrecan substrate. The cells were then stimulated with IL-1, and the aggrecan fragments generated could be analyzed. Alternatively, the spent medium could be used for analyzing enzymes or other products. We adopted this approach because control of aggrecan breakdown by chondrocytes is dynamic, tightly controlled, and not well understood. It is widely known that mRNA of ADAMTS-5, which is a major aggrecanase implicated in mediating cartilage damage in murine models, shows little or no increase in human chondrocytes stimulated with IL-1.
An additional difficulty in understanding aggrecan degradation lies in determining and measuring the different forms of aggrecanase proteins, because of a lack of antibodies suitable for Western blotting the low (picomolar) concentrations in cell cultures. ADAMTS enzymes have multiple domains that determine binding to extracellular matrix, substrate specificity, and interaction with the cell surface (17, 34) . Although we can measure total aggrecanase activity in spent culture medium, we do not understand which processed or modified forms are contributing to the measurement or which are most relevant to cleaving aggrecan in cartilage. Other factors confounding the analysis of aggrecan degradation include the presence of the inhibitor TIMP-3, as well as the fact that TIMP-3, ADAMTS-4, and ADAMTS-5 are all internalized by cells via LRP-1 (17, 29, 30) . LRP-1 is a promiscuous surface receptor that can bind and internalize at least 40 different proteins (31) .
Based on the results of these experiments, our main conclusions are that IL-1 causes aggrecan degradation by human chondrocytes via signaling through the JNK pathway, and that ADAMTS-5 is the major aggrecanase responsible for the IL-1-induced activity, with ADAMTS-4 playing a minor role. Our work is limited to the analysis of 2 major cleavages of aggrecan; the extent to which blocking JNK inhibits all aggrecan degradation is still being investigated.
The experiments in which LRP-1 was blocked with RAP showed that aggrecanase was secreted in resting cells, but that 98% of this was endocytosed. Knockdown of TIMP3 had no measurable effect on the amount of aggrecanase detected, suggesting that the enzyme is produced in larger amounts compared with the inhibitor. Stimulation by IL-1 also did not increase the amount of aggrecanase detectable using an Aggrecanase Activity Assay. The amount observed in the spent medium of the IL-1-stimulated cultures represented ;20% of the total amount produced. The lack of a clear increase in synthesis of active aggrecanase by stimulated cells, together with the efficient endocytosis of aggrecanase in resting cells, suggest a reduction in endocytosis during IL-1 stimulation as a possible means of regulation. The JNK-2-dependent shedding of LRP-1 and the reduction in its cellular and surface expression are consistent with this possibility. Further investigation is therefore needed to establish the relationship between LRP-1 shedding, the aggrecanase(s) that accumulate in the culture medium, and the form(s) of aggrecanase that cleave aggrecan in the overlay cell culture system and cartilage tissue.
The aggrecan cleavages in the overlay system were strikingly dependent on JNK-2, and although we did not achieve complete knockdown of JNK1, we expected to see some reduction in fragment generation if it were involved. Quantification of the individual JNK proteins is not possible, but the human chondrocytes stimulated with IL-1 appeared to have similar amounts of p-JNK-2 (the 54-kd band) and of the 46-kd band, which is likely to be mainly JNK-1. JNK-1 and JNK-2 are ubiquitous, while the expression of JNK-3 is mainly confined to the central nervous system (35) . It is not known whether the different JNKs have different downstream functions. A complete understanding of the physiologic functions of these kinases has been hindered by a lack of good pharmacologic inhibitors. Single-knockout JNK1 and JNK2 have no marked phenotype, while the double knockouts have an embryonically lethal phenotype (36) . Further work is required to determine whether the action of IL-1 on aggrecan degradation is mediated specifically by JNK2. Another question is whether activity in the JNK pathway determines the level of aggrecan degradation under normal physiologic conditions, or whether such activity comes into play only in a stress-related situation such as cytokine stimulation. A related question is whether JNK activity is sufficient for aggrecan degradation. Our experiments show that it is necessary in the context of IL-1 stimulation, although we did not observe that activation of NF-kB, p38, or ERK was contributing to degradation.
Our studies have been restricted to IL-1, but many factors affect JNK activity (35) . Among inflammatory stimuli, TNF, Toll-like receptor ligands, IL-17, and IL-18 all activate the same set of pathways, including JNKs. JNK is also activated by a variety of physical stress stimuli (35) , including simple mechanical injury of cartilage and synovium (37) . Thus, in OA, for example, in which the role of IL-1 is highly debatable, other JNK activators might determine pathology.
We speculated that the JNK-2-dependent shedding of LRP-1 might be a mechanism of reducing its surface expression, thereby increasing aggrecanase activity. Shedding of LRP-1 may be mediated by metalloproteinases (e.g., ADAM-9, ADAM-10, and ADAM-12) as well as other enzymes (38) , but how JNK-2 might control this mechanism is unknown. JNKs characteristically activate AP-1 transcription factors, which control expression of many genes.
